MY203401A - Methods and compositions for treating excessive sleepiness - Google Patents

Methods and compositions for treating excessive sleepiness

Info

Publication number
MY203401A
MY203401A MYPI2019007118A MYPI2019007118A MY203401A MY 203401 A MY203401 A MY 203401A MY PI2019007118 A MYPI2019007118 A MY PI2019007118A MY PI2019007118 A MYPI2019007118 A MY PI2019007118A MY 203401 A MY203401 A MY 203401A
Authority
MY
Malaysia
Prior art keywords
methods
compositions
treating excessive
excessive sleepiness
sleepiness
Prior art date
Application number
MYPI2019007118A
Other languages
English (en)
Inventor
Lawrence Patrick Carter
Yuan Lu
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64455104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY203401(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MY203401A publication Critical patent/MY203401A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
MYPI2019007118A 2017-06-02 2018-06-01 Methods and compositions for treating excessive sleepiness MY203401A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514176P 2017-06-02 2017-06-02
PCT/US2018/035532 WO2018222954A1 (en) 2017-06-02 2018-06-01 Methods and compositions for treating excessive sleepiness

Publications (1)

Publication Number Publication Date
MY203401A true MY203401A (en) 2024-06-26

Family

ID=64455104

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019007118A MY203401A (en) 2017-06-02 2018-06-01 Methods and compositions for treating excessive sleepiness

Country Status (12)

Country Link
US (7) US10959976B2 (enExample)
EP (1) EP3630072A4 (enExample)
JP (1) JP2020528075A (enExample)
KR (3) KR20200016889A (enExample)
CN (1) CN111201014A (enExample)
AU (1) AU2018278332B2 (enExample)
BR (1) BR112019025286A2 (enExample)
CA (1) CA3065522A1 (enExample)
MX (1) MX390786B (enExample)
MY (1) MY203401A (enExample)
PH (1) PH12019502723A1 (enExample)
WO (1) WO2018222954A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3630072A4 (en) 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
WO2021001457A1 (en) * 2019-07-04 2021-01-07 Sandoz Ag Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
MX2024002483A (es) * 2021-09-03 2024-03-14 Axsome Therapeutics Metodos y composiciones para mejorar biomarcadores asociados con riesgo cardiovascular usando carbamato de (r)-2-amino-3-fenilpropi lo.
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
EP4615426A1 (en) * 2022-11-07 2025-09-17 Axsome Therapeutics Compositions and methods for treating insomnia
EP4626417A1 (en) * 2022-11-30 2025-10-08 Axsome Therapeutics Methods and compositions for improving driving performance
US12064411B1 (en) * 2022-12-30 2024-08-20 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12036194B1 (en) 2022-12-30 2024-07-16 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12102609B2 (en) 2022-12-30 2024-10-01 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12090126B2 (en) 2022-12-30 2024-09-17 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12005036B1 (en) 2022-12-30 2024-06-11 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US11771666B1 (en) 2022-12-30 2023-10-03 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
AU2023415568A1 (en) * 2022-12-30 2025-07-03 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
CN121816178A (zh) * 2023-05-30 2026-04-07 艾克萨姆治疗股份有限公司 用于治疗患有与阻塞性睡眠呼吸暂停和白天过度嗜睡相关的认知受损的受试者的认知受损的索安非托
WO2025042959A1 (en) * 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases
WO2025064549A1 (en) * 2023-09-18 2025-03-27 Axsome Therapeutics, Inc. Solriamfetol for improving cognitive health in apnea patients

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
DE9311004U1 (de) 1993-07-23 1993-10-14 Mauser-Werke GmbH, 50321 Brühl Palettencontainer
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
DE69618663T2 (de) 1996-10-10 2002-08-14 Sk Corp., Seoul/Soul O-carbamoyl-phenylalaninol-zusammensetzungen und ihre pharmazeutisch anwendbaren salzen
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
AU779354B2 (en) 1998-12-23 2005-01-20 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CZ20032311A3 (cs) 2001-02-27 2005-02-16 Ortho-Mcneil Pharmaceutical, Inc. Karbamátová sloučenina a léčivo pro prevenci a léčení úzkosti
CZ20032300A3 (cs) 2001-02-27 2005-01-12 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro prevenci nebo léčbu bipolárních chorob
DE60221670T2 (de) 2001-02-27 2008-04-30 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
NZ537543A (en) 2002-07-29 2007-08-31 Alza Corp Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
KR20070083826A (ko) 2004-10-28 2007-08-24 에스케이 주식회사 우울증을 위한 부가 요법
AU2006254899B2 (en) 2005-06-08 2011-11-24 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
DE602006012670D1 (de) 2005-06-22 2010-04-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
CA2616721C (en) 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
RU2567801C2 (ru) 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
WO2011055944A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
WO2011139271A1 (en) 2010-05-04 2011-11-10 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
EP2392325A1 (en) 2010-06-04 2011-12-07 Universitätsklinikum Münster Compounds for the prevention and/or treatment of osteoarthrosis
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9359290B2 (en) 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
JP2016530240A (ja) 2013-07-12 2016-09-29 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ 禁煙の促進
PL3021838T3 (pl) 2013-07-18 2021-03-08 Jazz Pharmaceuticals Ireland Limited Leczenie otyłości
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3630072A4 (en) 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Also Published As

Publication number Publication date
US20240033243A1 (en) 2024-02-01
MX390786B (es) 2025-03-21
JP2020528075A (ja) 2020-09-17
WO2018222954A1 (en) 2018-12-06
US20200163927A1 (en) 2020-05-28
US20240180866A1 (en) 2024-06-06
MX2019014409A (es) 2022-03-17
US20200281886A1 (en) 2020-09-10
AU2018278332A1 (en) 2020-01-30
US11648232B2 (en) 2023-05-16
US11865098B1 (en) 2024-01-09
KR20230145525A (ko) 2023-10-17
AU2018278332B2 (en) 2022-05-19
EP3630072A4 (en) 2021-03-10
US10959976B2 (en) 2021-03-30
US20210205257A1 (en) 2021-07-08
KR20200016889A (ko) 2020-02-17
BR112019025286A2 (pt) 2020-06-23
CN111201014A (zh) 2020-05-26
KR20240162165A (ko) 2024-11-14
NZ760594A (en) 2025-05-02
US20250114322A1 (en) 2025-04-10
EP3630072A1 (en) 2020-04-08
US20240189270A1 (en) 2024-06-13
PH12019502723A1 (en) 2020-07-13
KR102726728B1 (ko) 2024-11-05
US10912754B2 (en) 2021-02-09
CA3065522A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
PH12019502723A1 (en) Methods and compositions for treating excessive sleepiness
CY1124121T1 (el) Εκλεκτικοι ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφικης συνθεσης
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
SA521422063B1 (ar) تركيبات وطرق لتعديل نشاط ديهيدروجيناز بسلسلة قصيرة
PH12017501611A1 (en) Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
PH12019502886A1 (en) Methods for increasing growth of beneficial bacteria in the gastrointestinal tract
SA520411187B1 (ar) نظائر فينيل ألانينول كربامويل واستخداماتها
PH12017500639A1 (en) Neuroactive compounds and methods of use thereof
DOP2007000015A (es) Usos terapéuticos de inhibidores de rtp801
MX2024005935A (es) Metodos para aumentar la exposicion al plasma de sepiapterina.
EP4345110A3 (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
PH12019501408A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
GEP20247644B (en) Inhibitors of adrenoreceptor adrac2
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
PH12019501458A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
MX2023015250A (es) Metodos para tratar la apnea obstructiva del sue?o.
ZA202002936B (en) Phenoxy acids for the treatment of neuromuscular disorders
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
GB201904373D0 (en) Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
GB2574747A (en) Use of lambda interferons in the treatment of obesity-related disorders and related diseases